Compare ERC & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERC | CYBN |
|---|---|---|
| Founded | 2003 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.1M | 298.9M |
| IPO Year | N/A | N/A |
| Metric | ERC | CYBN |
|---|---|---|
| Price | $9.41 | $6.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $74.50 |
| AVG Volume (30 Days) | 64.4K | ★ 621.7K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 8.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.51 | $4.81 |
| 52 Week High | $9.74 | $10.80 |
| Indicator | ERC | CYBN |
|---|---|---|
| Relative Strength Index (RSI) | 52.71 | 49.09 |
| Support Level | $9.20 | $5.50 |
| Resistance Level | $9.49 | $6.23 |
| Average True Range (ATR) | 0.10 | 0.33 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 74.77 | 63.12 |
Allspring Multi-Sector Income Fund is a closed-end investment management company. The company's core business is to secure a high level of income for its investors consistent with limiting its overall exposure to domestic interest rate risk. It invests in U.S. dollar-denominated below investment-grade bonds, debentures, and other income obligations, including loans and preferred stocks, developed and emerging market debt securities, including obligations of foreign governments or governmental entities, foreign corporations, or supranational agencies denominated in various currencies, asset backed securities and investment grade corporate bonds.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.